טוען...
Use of a KIT-specific monoclonal antibody to bypass imatinib resistance in gastrointestinal stromal tumors
Acquired resistance to imatinib is a significant problem for the clinical management of gastrointestinal stromal tumor (GIST) patients, and second-line small molecules have shown limited efficacy in this setting. We have recently demonstrated that a monoclonal antibody targeting KIT could potentiall...
שמור ב:
| Main Authors: | , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Landes Bioscience
2013
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3716740/ https://ncbi.nlm.nih.gov/pubmed/23894705 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/onci.24452 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|